biOasis Advances its Herceptin(R) BT2111 Program - MarketWatch
|
biOasis Technologies Inc. announced today that work is underway at Texas Tech University Health Sciences Center (TTUHSC) to perform a series of preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of p97 and Herceptin(R)) in animal models of breast cancer metastasis in the brain. The studies at TTUHSC will be conducted under the direction of Drs. Quentin Smith and Paul Lockman - both recognized experts in the blood-brain barrier and in evaluating drug delivery to the central nervous system for the treatment of brain tumors. Read the full story >> |
Related Stories
TTUHSC Names New Regional Dean for the School of Nursing
Louise Rice, DNP, RN, has been named regional dean of the TTUHSC School of Nursing on the Amarillo campus.
A Call for Change: Addressing the Invisible Workload of School-Based SLPs
Tobias Kroll, Ph.D., CCC-SLP, an Associate Professor in the Department of Speech, Language and Hearing Sciences, discusses the workloads and expectations of school-based SLPs.
Noise-Induced Hearing Loss in Rural Adolescents
Leigh Ann Reel, Au.D., Ph.D., CCC-A, discussed the causes and prevention strategies for noise-induced hearing loss, particularly for adolescents in rural areas.
Recent Stories
TTUHSC MAT Students Receive Coveted NFL Internships
Jill Manners, ScD, LAT, ATC, PT, NREMT, COMT, FNAP, is giving us a closer look into the NFL internship opportunities that some of the MAT students are experiencing over the summer.
Collaborative Team Earns Five-Year Renewal Grant from NINDS to Continue Stroke Research
Due to this high level of productivity and potential to create new medications for stroke injury, NINDS recently awarded a new $3 million competitive renewal that extends the grant for an additional five years.
Keep Pushing: PA Alumni Gives Back
Jemimah Omavuezi, DMS, MPAS, PA-C, used her own story as inspiration to create the Omavuezi Scholarship for others.